Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results

First-Quarter 2023 Results:
-- Net Sales of $832.1 Million --
-- GAAP Net Income of $54.7 Million; Adjusted EBITDA of $232.9 Million --
-- TEPEZZA® Net Sales of $405.3 Million --
--... | May 3, 2023

Related Keywords

Ireland ,Japan ,Ukraine ,United States ,Russia ,Tim Walbert ,Viela Bio Inc ,Companies To Work ,Nasdaq ,Top Biotechnology Pharmaceutical Company ,Facebook ,Clinical Program Expected To ,Instagram ,Amgen Inc ,Linkedin ,Apotex Inc ,Amgen ,United States Federal Trade Commission ,Twitter ,Net Sales ,Recent Company Highlights ,Positive Topline Data ,Low Clinical Activity Score ,Thyroid Eye Disease ,Specify Treatment ,Disease Activity ,Second Population ,Syndrome Phase ,Only Phase ,Syndrome Trial ,Primary Endpoint ,Both Patient Populations ,Program Expected ,Two Daxdilimab Phase ,Discoid Lupus Erythematosus ,Expect Amgen Transaction ,Work For ,Pharmaceutical Company ,Third Consecutive ,Quarterly Report ,Investor Relations ,Regarding Use ,Consolidated Statements ,Months Ended March ,Consolidated Balance Sheets ,Cash Flows ,Earnings Per Share ,Per Share ,Operating Cash Flow ,Rate Reconciliation ,Income Statement Line Items ,Three Months Ended March ,Lake Forest ,Viela Bio ,Horizon Therapeutics Public Limited Company Stock Exchange ,News ,Information ,Press Release ,023 ,Pet ,Sales ,F ,Billion ,Aap ,Income ,Djusted ,Bitda ,Illion Hznp Ie00bqpvqz61 ,